doctor sikiric bpc-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded BPC-157: Miracle Healing Peptide or

Marta Stevanovic of Massachusetts Eye and Ear spoke with Host and JVRD Editor-in-Chief Tim Murray, MD MBA, about Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD, published in the July/August 2025 issue of JVRD

[email protected] *Correspondence: [email protected] (M.B.)

The unadjusted cause-specific hazard ratios were 1.27 (95% CI, 1.211.35) for ischemic stroke and 1.46 (95% CI, 1.301.65) for intracerebral hemorrhage over 0-30 years follow-up

Investment in peptide drug development by pharmaceutical companies continues to increase, reflecting confidence in the therapeutic potential and commercial viability of this drug class

Clearer thinking often emerges when anxiety decreases

The data suggested that GHK may preferentially interact with hydroxyl and peroxyl radicals, while exhibiting more limited activity toward superoxide-related species